Academic literature on the topic 'Maladies de surcharge lysosomale'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Maladies de surcharge lysosomale.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Maladies de surcharge lysosomale"
Germain, Dominique P. "Lysosomes et Maladies de Surcharge Lysosomale." Journal de la Société de Biologie 196, no. 2 (2002): 127–34. http://dx.doi.org/10.1051/jbio/2002196020127.
Full textMaroteaux, Pierre. "Maladies de surcharge lysosomale : approache clinique." Revue Française des Laboratoires 1998, no. 303 (May 1998): 27–29. http://dx.doi.org/10.1016/s0338-9898(98)80063-2.
Full textMaier-Redelsperger, Micheline, and Odile Fenneteau. "Aspects cytologiques des maladies de surcharge lysosomale." Revue Française des Laboratoires 1998, no. 303 (May 1998): 31–35. http://dx.doi.org/10.1016/s0338-9898(98)80064-4.
Full textGuffon, Nathalie, and Gérard Souilett. "Thérapeutiques actuelles des maladies de surcharge lysosomale." Revue Française des Laboratoires 1998, no. 303 (May 1998): 41–44. http://dx.doi.org/10.1016/s0338-9898(98)80066-8.
Full textChabraoui, L., H. Talbaoui, and C. Caillaud. "Épidémiologie des maladies de surcharge lysosomale au Maroc." Revue Francophone des Laboratoires 2009, no. 416 (November 2009): 33–34. http://dx.doi.org/10.1016/s1773-035x(09)70278-3.
Full textFenneteau, Odile, and Micheline Maier-Redelsperger. "Aspects cytologiques des maladies métaboliques hérédiatires (hors maladies de surcharge lysosomale)." Revue Française des Laboratoires 1998, no. 303 (May 1998): 49–53. http://dx.doi.org/10.1016/s0338-9898(98)80068-1.
Full textMaire, Irène. "Diagnostic biologique et moléculaire des maladies de surcharge lysosomale." Revue Française des Laboratoires 1998, no. 303 (May 1998): 37–40. http://dx.doi.org/10.1016/s0338-9898(98)80065-6.
Full textZenone, T., K. Blanc-Lasserre, F. Skowron, C. Deprêle, and M. Raoulx. "Prévalence des maladies de surcharge lysosomale en Drôme-Ardèche." La Revue de Médecine Interne 31 (June 2010): S173. http://dx.doi.org/10.1016/j.revmed.2010.03.295.
Full textGirard, Sandrine, Odile Fenneteau, and Marine Delecourt-Billet. "Anomalies cytologiques sanguines au cours des maladies de surcharge lysosomale." Revue Francophone des Laboratoires 2021, no. 536 (November 2021): 46–51. http://dx.doi.org/10.1016/s1773-035x(21)00224-0.
Full textÉmile, Carole. "Anomalies cytologiques et diagnostic biochimique des maladies de surcharge lysosomale." Option/Bio 34, no. 679-680 (November 2023): 28–30. http://dx.doi.org/10.1016/s0992-5945(23)00357-4.
Full textDissertations / Theses on the topic "Maladies de surcharge lysosomale"
Hippert, Claire. "Etudes de transfert de gène pour une maladie de surcharge lysosomale, la cystinose." Montpellier 2, 2009. http://www.theses.fr/2009MON20118.
Full textCystinosis is a lysosomal storage disorder characterised by a defective lysosomal cystine efflux. The causative gene, CTNS, encodes the lysosomal cystine transporter, cystinosin. Storage of cystine, which forms crystals at high levels, disrupts the function of different organs at different rates. Cysteamine, the only treatment currently available to reduce lysosomal cystine levels, has dramatically improved the life of patients. However, due to its administration constraints and side effects, we explored the feasibility of viral-mediated CTNS gene therapy to reduce cystine levels in cystinosin-deficient (Ctns-/-) mice. The main part of my PhD was concentrated on in vivo gene transfer studies to the liver using CTNS-expressing human adenovirus vectors (hAd). This work provided for the first time the proof-of-concept that viral-mediated CTNS gene transfer can correct a lysosomal transport defect, but suggests that, in the case of cystinosis, it could be preventive but not curative in some tissues. Rather than attempting a mulisystemic gene therapy to cystinosis, we specifically concentrated on treating the ocular and CNS anomalies, which are incapacitating and have the potential to be life-threatening. Thus, along this line, we characterised these anomalies in Ctns-/- mice : we showed that they mimic those of patients and, in parallel, generated a temporospatial guide to their appearance, an essential tool for testing novel ocular and CNS cystine-depleting therapies. The next step of this work was to begin gene transfer studies in these structures using more clinically relevant vectors than hAd vector: an helper dependant canin adenovirus and an adeno-associated virus
Ruivo, Raquel. "Molecular physiology and pathophysiology of two lysosomal transporters : sialin and cystinosin." Paris 11, 2009. http://www.theses.fr/2009PA11T083.
Full textAndrzejewska, Zuzanna. "Study of the lysosomal trafficking of cystinosin and its role in the mTORC1 pathway." Thesis, Paris 5, 2013. http://www.theses.fr/2013PA05T061.
Full textPas de résumé en anglais
Denard, Jérôme. "Développement d'une approche de thérapie génique pour l'amyotrophie spinale avec épilepsie myoclonique progressive." Electronic Thesis or Diss., université Paris-Saclay, 2023. https://www.biblio.univ-evry.fr/theses/2023/interne/2023UPASL144.pdf.
Full textSpinal muscular atrophies are a heterogeneous group of disorders characterized by spinal cord α-motor neuron degeneration, leading muscle weakness and atrophy. The most common form is associated to mutations in the SMN1 gene, for which a gene therapy product obtained marketing approval. Another form of spinal muscular atrophy with progressive myoclonic epilepsy (SMA-PME), is due to mutations in the ASAH1 gene encoding a lysosomal enzyme,the acid ceramidase (ACDase). The life expectancy of patients with SMA-PME does not exceed adolescence. Some mutations in this same gene can cause Farber disease (FD), with the most severe forms causing death of patients before the age of 2 years due to severe multisystemic damage. SMA-PME and FD are ultra-rare lysosomal storage diseases. ACDase catalyzes the bioactive lipid ceramide into sphingosine and fatty acid. Due to the deficiency of enzyme activity, ceramides accumulate inside lysosomes causing serious dysfunctions in several organs. A therapeutic approach based on hematopoietic stem cell transplantation was previously tested in Farber patients but did not prevent neurological deterioration over time. The generation of mouse models of ACDase deficiency, in particular the Asah1P361R/P361R model that recapitulates the signs of Farber disease, has allowed a better understanding of the pathophysiology of acid ceramidase deficiency in tissues and the evaluation of different therapeutic approaches. Enzyme replacement therapy and gene therapy using a lentiviral vector extended the survival of mutant animals by several weeks, but did not correct the neurological signs of the disease. Since there is no curative treatment for patients, the main goal of my thesis project was to develop an efficacious gene therapy approach using an AAV vector. Intravenous administration of an AAV9-ASAH1 vector in Asah1P361R/P361R mice at pre- and symptomatic stages of the disease was able to prolong the lifespan and correct the phenotype. This approach provided proof of concept that generalized restoration of ASAH1 gene expression achieves a therapeutic effect in a severe mouse model of acid ceramidase deficiency. These results prompted us to perform a dose escalation study in Asah1P361R/P361R mice to determine the minimum effective dose of this vector. Three doses of AAV9-ASAH1 were administered intravenously in mutant mice at a late stage of the disease and the effect was analyzed at the clinical, molecular and histological level for a 6-month period. We identified a vector dose able to correct the phenotype and to avoid macrophage infiltrates in tissues, including the central nervous system. Intracerebroventricular administration (ICV) of the AAV9-ASAH1 vector in neonatal mutant mice was also evaluated to investigate the efficacy of this direct route of administration in correcting the neurological signs of the disease. The results show that systemic injection of the AAV9-ASAH1 vector was able to correct the whole-body phenotype of Asah1P361R/P361R mutant mice, whereas preliminary results indicate that ICV administration of the vector is efficacious in preventing mainly the neurological signs of the disease. This thesis work paves the way for clinical translation of this gene therapy in patients with Farber and SMA-PME diseases
Roy, Elise. "Cell disorders in lysosomal storage diseases." Phd thesis, Université René Descartes - Paris V, 2012. http://tel.archives-ouvertes.fr/tel-00683248.
Full textBarr, Caroline. "Évaluation de l'excrétion urinaire d'un biomarqueur pour la maladie de Fabry, le globotriaosylcéramide (Gb[indice inférieur 3]), chez des enfants normaux de la naissance à 6 mois." Mémoire, Université de Sherbrooke, 2009. http://savoirs.usherbrooke.ca/handle/11143/4010.
Full textWoronoff, Anne-Sophie. "Cystinose juvenile : maladie de surcharge lysosomiale , a propos d'une observation familiale avec atteinte renale." Besançon, 1994. http://www.theses.fr/1994BESA3084.
Full textDa, Silva Afitz. "Glycovecteurs pour le ciblage thérapeutique d'une maladie rare lysosomale : la maladie de Pompe." Thesis, Montpellier, 2017. http://www.theses.fr/2017MONTT001.
Full textOn 53 known rare lysosomal diseases, only 8 can be treated by enzyme replacement therapy with more or less efficiency. There is therefore a need to develop new treatments but also to better characterize these diseases. During this thesis, we focused on Pompe disease which results from the absence or deficiency of the lysosomal enzyme alpha-glucosidase acid (GAA), responsible for the degradation of glycogen in glucose in many tissues. Currently only the infantile form of this disease can be treated while the juvenile/adult form is slightly improved by Myozyme® treatment. This thesis aimed to devel a new enzyme replacement therapy which could prevent the progression of the disease and satisfactorily treat the late onset form of the disease. To do that, we used monosaccharide derivatives “Mannose-6-phosphate analogues (M6P) Functionalized on Aglycone (AMFA)”, which were grafted onto human recombinant GAA (rhGAA) in order to improve its lysosome addressing obtaining the rhGAA-AMFA.A first in vitro study on adult patient fibroblasts showed that the addition of AMFA to rhGAA, produced in Sf9 insect cells, significantly improved its affinity for the M6P receptor (RM6P), its internalization and activity. It was also more efficient on the GAA-/- Pompe mouse model compared to current treatment (Article 1). Then, we demonstrated for the first time the efficiency of rhGAA-AMFA produced in CHO cells in aged mice model. These results suggest the possibility to use this neo-enzyme in the treatment of the adult form that still resists to treatment (Article 2). Finally, the addition of AMFA allows a complete maturation of rhGAA into its active form in myoblasts and myotubes of adult patients and in the quadriceps of aged mice Pompe model. This was not observed for Myozyme® (Article 3). In this thesis we have also demonstrated that novel disaccharide analogues with a better affinity than monosaccharides for RM6P can efficiently target GAA for the treatment of Pompe disease. A patent has been filed on these results (Patent PCT / FR2016 / 052339).In conclusion, this work has led to the development of a new technology more efficient in targeting lysosomal enzymes by mean of new synthetic analogues. An orphan drug designation for the recombinant human acid alpha-glucosidase conjugated with mannose-6-phosphate analogues was obtained on the basis of this work at the European Medicines Agency for the treatment of Pompe disease (EMA/OD/098/16).Key words: lysosomal diseases, Pompe disease, enzyme replacement therapy, mannose 6-phosphate receptor
Hilaire, Nathalie. "Métabolisme cellulaire des lipides neutres cytoplasmiques et myopathie à surcharge lipidique multisystémique." Toulouse 3, 1994. http://www.theses.fr/1994TOU30051.
Full textTardy, Claudine. "Rôle des protéases lysosomales dans l'apoptose : relation avec la physiopathologie des maladies lysosomales." Toulouse 3, 2004. http://www.theses.fr/2004TOU30143.
Full textLysosomes are cellular organelles which contain numerous enzymes for degradation of macromolecules. For many years, they have been considered as suicide bags that would release unspecific digestive enzymes after uncontrolled cell damage. However, some lysosomal proteases have been recently suggested to act as cell death mediators. This work aimed at analyzing the role of lysosomal proteases in apoptosis. We investigated the implication of lysosomal proteases in cell death by using fibroblasts isolated from patients with either I-cell disease, a lysosomal targeting defect, or neuronal ceroid lipofuscinoses (due to a single lysosomal defect). We have shown that these fibroblasts are partially resistant to TNF-induced cell death as compared to control cells. Our results indicate that Tripeptidyl peptidase 1 (TPP1) and Palmitoyl-protein thioesterase 1 (PPT1), two lysosomal hydrolases, may contribute to TNF-induced apoptosis
Books on the topic "Maladies de surcharge lysosomale"
Guide photographique de portions alimentaires pour l’estimation des quantités consommées au Cameroun. EDP Sciences, 2021. http://dx.doi.org/10.1051/978-2-7598-2456-4.
Full textBook chapters on the topic "Maladies de surcharge lysosomale"
Bolognia, Jean L., Julie V. Schaffer, Karynne O. Duncan, and Christine J. Ko. "Maladies de surcharge." In Dermatologie : L'essentiel, 365–67. Elsevier, 2023. http://dx.doi.org/10.1016/b978-2-294-77853-7.00040-8.
Full text